1st May 2019

Beatson Institute researchers have unravelled a new way to maximise the production of important cancer-related proteins for study in the laboratory.  This work, led by Dr Chris Gray of the Institute’s Drug Discovery Programme, has demonstrated that subtle changes to the genetic instructions given to bacterial protein factories can dramatically improve the recovery of high-quality proteins. 

The work has been published in PLoS One.  

These findings refine and optimise current recombinant technologies, used globally for the production of proteins for the laboratory and the clinic.  As a consequence of this discovery, larger amounts of key reagents can be delivered to our drug discovery programmes, accelerating the development of new therapies.

Click here to read more about the Drug Discovery Programme.